Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 4/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776786 | 0.82 | DHODH (0.53) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL4234917 | 0.80 | DHODH (0.60) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL3587309 | 0.76 | PDE10A (0.57) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL4245187 | 0.76 | DHODH (0.65) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL14492079 | 0.76 | PDE10A (0.68) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL8267472 | 0.76 | LMNA (0.82) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL6957665 | 0.76 | DHODH (0.65) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL1581252 | 0.76 | DHODH (0.65) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL3580968 | 0.75 | PDE10A (0.56) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL4772693 | 0.74 | DHODH (0.56) | DHODHLMNAPDE10ATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| EP-1940795-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007035156-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | TACR3, TACR2, KCNA3 | DHODH 2182/4885LMNA 2876/4885PDE10A 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.